CN117016486B - 一种IgA肾病合并膜性肾病的动物模型构建方法 - Google Patents
一种IgA肾病合并膜性肾病的动物模型构建方法 Download PDFInfo
- Publication number
- CN117016486B CN117016486B CN202310892388.XA CN202310892388A CN117016486B CN 117016486 B CN117016486 B CN 117016486B CN 202310892388 A CN202310892388 A CN 202310892388A CN 117016486 B CN117016486 B CN 117016486B
- Authority
- CN
- China
- Prior art keywords
- week
- dose
- mice
- cbsa
- nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010171 animal model Methods 0.000 title claims abstract description 40
- 206010018372 Glomerulonephritis membranous Diseases 0.000 title claims abstract description 22
- 201000008350 membranous glomerulonephritis Diseases 0.000 title claims abstract description 22
- 231100000855 membranous nephropathy Toxicity 0.000 title claims abstract description 22
- 208000010159 IgA glomerulonephritis Diseases 0.000 title claims abstract description 18
- 238000010276 construction Methods 0.000 title claims description 8
- 206010021263 IgA nephropathy Diseases 0.000 title description 4
- 238000002474 experimental method Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 8
- 241000699670 Mus sp. Species 0.000 claims description 36
- 238000000465 moulding Methods 0.000 claims description 17
- 210000003462 vein Anatomy 0.000 claims description 7
- 239000007928 intraperitoneal injection Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 abstract description 15
- 229940099472 immunoglobulin a Drugs 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000001434 glomerular Effects 0.000 abstract description 5
- 206010020718 hyperplasia Diseases 0.000 abstract description 5
- 210000002469 basement membrane Anatomy 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000008085 renal dysfunction Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- 229940098773 bovine serum albumin Drugs 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 238000011725 BALB/c mouse Methods 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000005084 renal tissue Anatomy 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000009535 clinical urine test Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 210000000585 glomerular basement membrane Anatomy 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
试验组 | 血清(μg/mL) | 肾脏(μg/mg) |
G1平均值 | 113.49 | 0.16 |
SEM | 5.46 | 0.02 |
G2平均值 | 271.01 | 0.59 |
SEM | 64.86 | 0.09 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310892388.XA CN117016486B (zh) | 2023-07-20 | 2023-07-20 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310892388.XA CN117016486B (zh) | 2023-07-20 | 2023-07-20 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117016486A CN117016486A (zh) | 2023-11-10 |
CN117016486B true CN117016486B (zh) | 2024-05-14 |
Family
ID=88636358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310892388.XA Active CN117016486B (zh) | 2023-07-20 | 2023-07-20 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117016486B (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000232884A (ja) * | 1997-12-25 | 2000-08-29 | Japan Tobacco Inc | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
WO2000073791A1 (en) * | 1999-05-27 | 2000-12-07 | Tanabe Seiyaku Co., Ltd. | Remedies for kidney diseases and method for screening the same |
CN105434447A (zh) * | 2014-08-28 | 2016-03-30 | 复旦大学 | 一种慢性肾脏病血管钙化实验模型的建立方法 |
CN105566498A (zh) * | 2009-08-31 | 2016-05-11 | Ibc药品公司 | 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途 |
WO2018071701A1 (en) * | 2016-10-13 | 2018-04-19 | University Of Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
CN108935316A (zh) * | 2018-07-27 | 2018-12-07 | 上海中医药大学附属曙光医院 | 一种IgA肾病小鼠肾功能不全模型的建立方法 |
CN110970131A (zh) * | 2019-10-24 | 2020-04-07 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
CA3154164A1 (en) * | 2019-09-19 | 2021-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating membranous nephropathy |
CN112568188A (zh) * | 2021-02-24 | 2021-03-30 | 澎立生物医药技术(上海)有限公司 | 一种制作Brown Norway大鼠肺纤维化模型的方法 |
WO2022226352A1 (en) * | 2021-04-23 | 2022-10-27 | Pandion Operations, Inc. | Kidney-glomerular targeted immunotherapy |
WO2022236335A1 (en) * | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230137242A1 (en) * | 2020-01-31 | 2023-05-04 | Warszawski Uniwersytet Medyczny | Method of screening for a chronic kidney disease or glomerulopathy method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy |
-
2023
- 2023-07-20 CN CN202310892388.XA patent/CN117016486B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000232884A (ja) * | 1997-12-25 | 2000-08-29 | Japan Tobacco Inc | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
WO2000073791A1 (en) * | 1999-05-27 | 2000-12-07 | Tanabe Seiyaku Co., Ltd. | Remedies for kidney diseases and method for screening the same |
CN105566498A (zh) * | 2009-08-31 | 2016-05-11 | Ibc药品公司 | 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途 |
CN105434447A (zh) * | 2014-08-28 | 2016-03-30 | 复旦大学 | 一种慢性肾脏病血管钙化实验模型的建立方法 |
WO2018071701A1 (en) * | 2016-10-13 | 2018-04-19 | University Of Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
CN110177557A (zh) * | 2016-10-13 | 2019-08-27 | 莱斯特大学 | 用于减少患有免疫球蛋白a肾病的人受试者中的蛋白尿的方法 |
CN108935316A (zh) * | 2018-07-27 | 2018-12-07 | 上海中医药大学附属曙光医院 | 一种IgA肾病小鼠肾功能不全模型的建立方法 |
CA3154164A1 (en) * | 2019-09-19 | 2021-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating membranous nephropathy |
CN110970131A (zh) * | 2019-10-24 | 2020-04-07 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
CN112568188A (zh) * | 2021-02-24 | 2021-03-30 | 澎立生物医药技术(上海)有限公司 | 一种制作Brown Norway大鼠肺纤维化模型的方法 |
WO2022226352A1 (en) * | 2021-04-23 | 2022-10-27 | Pandion Operations, Inc. | Kidney-glomerular targeted immunotherapy |
WO2022236335A1 (en) * | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
Non-Patent Citations (7)
Title |
---|
characteristics of patients with coexisting IgA nephropathy and membranous nephropathy;Pei Chen等;renal failure;20180405;第40卷(第1期);第213-218页 * |
IgA肾病与膜性肾病患者肠道微生物菌群结构分析;赵娟;微生物学通报;20230228;第50卷(第2期);第632-643页 * |
合并慢性前列腺炎的慢性肾脏病患者临床病理特点;邱晓剑;庄永泽;杨家辉;;中国中西医结合肾病杂志;20100720(第07期);第603-605页 * |
壮肾固精方治疗血尿为主IgA肾病临床疗效观察;刘新;路金华;黄彩兰;;中国优生与遗传杂志;20170625(第06期);第121-122页 * |
大鼠慢性牙周炎与IgA肾病复合模型血清中MMP-3的表达及意义;王丽娜;李静;刘健;桑晓红;张静;;口腔医学研究;20131128(第11期);第995-998页 * |
银屑病相关性IgA肾病的临床病理分析;张苏华;唐政;陈惠萍;曾彩虹;刘志红;黎磊石;;肾脏病与透析肾移植杂志;20070630(第03期);第233-237+282页 * |
非人灵长类动物慢性肾病模型研究进展;陈波;谭睿陟;王丽;樊均明;;动物医学进展;20170520(第05期);第103-107页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117016486A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellomo et al. | Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure | |
Fairbanks et al. | Homozygous hemoglobin E mimics β‐thalassemia minor without anemia or hemolysis: Hematologic, functional, and biosynthetic studies of first north American cases | |
CN112237168A (zh) | 用马兜铃酸i或其联合四氯化碳构建小鼠肝癌模型的方法 | |
CN115152700B (zh) | 胶体锰佐剂在制备原发性干燥综合征动物模型中的应用 | |
CN117016486B (zh) | 一种IgA肾病合并膜性肾病的动物模型构建方法 | |
CN106573056A (zh) | 用于诊断和治疗炎症性肠病的方法和组合物 | |
CN113424795B (zh) | 一种急性胰腺炎动物模型的构建方法和用途 | |
KR20150065931A (ko) | 병용 요법 및 치료에 대한 내성 평가 방법 | |
CN103705567A (zh) | 一种当归补血颗粒及其制备方法 | |
Wilkes et al. | Postnatal maturation of mast cell subpopulations in the rat respiratory tract. | |
Eyre et al. | Acute systemic anaphylaxis in the horse | |
Ikoma et al. | Mechanism of the unique susceptibility of deep cortical glomeruli of maturing kidneys to severe focal glomerular sclerosis | |
Polito et al. | Urinary sodium and potassium excretion in idiopathic hypercalciuria of children | |
CN113303285B (zh) | 一种血小板特异抗原诱导猴itp模型的构建方法 | |
Gimson et al. | Fulminant hepatic failure and artificial liver support | |
Cooke et al. | Acute folic acid deficiency of unknown aetiology: temperate sprue | |
Arnott et al. | Experimental Glomerulo-Nephritis Produced by the Use of Specific Sera | |
Hopkin et al. | Variation in response to cytotoxicity of cigarette smoke. | |
Tagoe et al. | Amyloidogenesis is neither accelerated nor enhanced by injections of preformed fibrils in mice transgenic for wild-type human transthyretin: the question of infectivity | |
CN114766430B (zh) | 胎源性自闭症动物模型的构建方法及其应用 | |
CN114698592B (zh) | 一种干燥综合征肾损害小鼠模型的构建方法及其应用 | |
Ramirez et al. | Perinatal intermittent hypoxia increases early susceptibility to ANG II-induced hypertension in adult male but not in female Sprague–Dawley rats | |
MACKAY et al. | Lipoid nephrosis: report of a case of unusual duration | |
KR20230108417A (ko) | 염증성 장질환 환자 면역 시스템 모사 아바타 모델과 약물 스크리닝 플랫폼 | |
US5602302A (en) | Models for asthma guinea pig |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240425 Address after: 200120 second floor, building 14, No. 121 Longgui Road, Pudong New Area, Shanghai Applicant after: Shanghai Pengli Biotechnology Pharmaceutical Research Co.,Ltd. Country or region after: China Address before: Building 7, Lane 388, Galileo Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203 Applicant before: Pengli biomedical technology (Shanghai) Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |